Novo Nordisk’s Setback: What the CagriSema Trial Means for the Future of Obesity Drugs
Novo Nordisk’s stock experienced a significant 15% drop on Monday after announcing its next-generation weight loss drug, CagriSema, did not demonstrate superiority to Eli Lilly’s tirzepatide in a recent trial. This news arrives as Eli Lilly’s drugs, Mounjaro and Zepbound, are already gaining ground on Novo Nordisk’s established medications, Ozempic and Wegovy, in U.S. Prescriptions.
CagriSema’s Performance: A Closer Look at the Data
The trial revealed that patients taking a 2.4 mg dose of CagriSema achieved a weight loss of 23% after 84 weeks, compared to 25.5% weight loss observed in patients taking a 15 mg dose of tirzepatide. While CagriSema showed positive results, it fell short of demonstrating non-inferiority to its competitor.
The Rise of Tirzepatide and the Competitive Landscape
Tirzepatide, the active ingredient in Mounjaro and Zepbound, has quickly become a dominant force in the weight loss market. This trial result represents another challenge for Novo Nordisk, particularly following a near 50% decline in its stock value in 2025. The company is now exploring additional trials for CagriSema, including testing higher-dose combinations, hoping to unlock its full potential.
Novo Nordisk’s Future Strategy: Beyond CagriSema
Despite the setback, Novo Nordisk remains optimistic about CagriSema, which combines semaglutide and cagrilintide. Chief Scientific Officer Martin Holst Lange emphasized the potential of this combination, stating it could be the first GLP-1/amylin-combination product on the market. The company plans further trials to assess the drug’s complete weight-loss capabilities.
However, the trial results coincide with Novo Nordisk’s prediction of a 5% to 13% decline in sales and profit growth in 2026. This forecast accounts for increased competition, pricing pressures in the U.S., and the impending loss of exclusivity for Wegovy and Ozempic in certain markets. CEO Mike Doustdar has cautioned investors to expect a period of decline before a potential recovery.
What Does This Mean for Patients?
The competition between Novo Nordisk and Eli Lilly is ultimately beneficial for patients, driving innovation and potentially lowering costs in the long run. While CagriSema’s current results are not as promising as initially hoped, ongoing research and development could lead to improved formulations and more effective treatments for obesity.
FAQ: The Obesity Drug Market
What is tirzepatide?
Tirzepatide is the active ingredient in Eli Lilly’s Mounjaro and Zepbound, medications used for weight loss and managing type 2 diabetes.
What is CagriSema?
CagriSema is Novo Nordisk’s next-generation weight loss drug, combining semaglutide and cagrilintide.
What does “non-inferiority” mean in a drug trial?
Non-inferiority means that the new drug performs at least as well as the existing treatment, without being significantly worse.
What are GLP-1 receptor agonists?
GLP-1 receptor agonists are a class of drugs that mimic a natural hormone to regulate appetite and blood sugar.
Want to learn more about the latest advancements in obesity treatment? Subscribe to our newsletter for regular updates and expert insights.
Worth a look